• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes.

作者信息

Vose Julie M, Levit Laura A, Hurley Patricia, Lee Carrie, Thompson Michael A, Stewart Teresa, Hofacker Janie, Bruinooge Suanna S, Hayes Daniel F

机构信息

Julie M. Vose, University of Nebraska, Omaha, NE; Laura A. Levit, Patricia Hurley, and Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Carrie Lee, University of North Carolina at Chapel Hill, Chapel Hill, NC; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; Teresa Stewart, New Mexico Cancer Care Alliance, Albuquerque, NM; Janie Hofacker, Association of American Cancer Institutes, Pittsburgh, PA; and Daniel F. Hayes, University of Michigan, Ann Arbor, MI.

出版信息

J Clin Oncol. 2016 Nov 1;34(31):3796-3802. doi: 10.1200/JCO.2016.69.6781.

DOI:10.1200/JCO.2016.69.6781
PMID:27601549
Abstract
摘要

相似文献

1
Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes.应对癌症临床试验中的行政和监管负担：美国临床肿瘤学会和美国癌症研究所协会主办的利益相关者调查与研讨会总结
J Clin Oncol. 2016 Nov 1;34(31):3796-3802. doi: 10.1200/JCO.2016.69.6781.
2
Moving the boundaries of international collaboration on clinical trials and QoL: experiences in oncology and legislation within the European Parliament.推动临床试验和生活质量国际合作的边界：肿瘤学的经验和欧洲议会的立法。
Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):43-5. doi: 10.1586/erp.12.91.
3
The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.妇科癌症协作组在提高卵巢癌临床试验水平方面的全球影响。
Int J Gynecol Cancer. 2011 May;21(4):746-9. doi: 10.1097/IGC.0b013e31821bb446.
4
Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.向美国食品药品监督管理局自愿和强制提交基因组数据的经验：第三届美国食品药品监督管理局-药物信息协会-药物基因组学工作组-美国制药研究与制造商协会-生物技术产业组织药物基因组学研讨会第一阶段总结报告
Pharmacogenomics J. 2006 Sep-Oct;6(5):296-300. doi: 10.1038/sj.tpj.6500380. Epub 2006 Mar 28.
5
CT2--the clinical trials control tower: overcoming barriers to opening oncology clinical trials.CT2——临床试验控制塔：克服肿瘤学临床试验启动的障碍
J Clin Oncol. 2007 Apr 1;25(10):1288; author reply 1288. doi: 10.1200/JCO.2006.10.3200.
6
Quality of life in cancer clinical trials: researchers, patients and policy makers.癌症临床试验中的生活质量：研究人员、患者和政策制定者。
Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):661-5. doi: 10.1586/erp.11.84.
7
Clinical trials and drug approvals continue to accelerate in China.在中国，临床试验和药物审批的速度持续加快。
Lancet Oncol. 2017 Jul;18(7):855. doi: 10.1016/S1470-2045(17)30406-0. Epub 2017 May 25.
8
Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.肿瘤临床试验的无形障碍：开展肿瘤临床试验时结构、基础设施及程序方面的障碍所产生的影响
J Clin Oncol. 2006 Oct 1;24(28):4545-52. doi: 10.1200/JCO.2005.05.0104.
9
Barriers in conducting clinical trials in oncology in the developing world: A cross-sectional survey of oncologists.发展中世界肿瘤学临床试验开展中的障碍：肿瘤学家横断面调查
Indian J Cancer. 2016 Jan-Mar;53(1):174-7. doi: 10.4103/0019-509X.180865.
10
Oncology trial design: More accurately and efficiently advancing the field.肿瘤学试验设计：更准确、高效地推动该领域发展。
Clin Pharmacol Ther. 2015 May;97(5):430-2. doi: 10.1002/cpt.94.

引用本文的文献

1
A framework for assessing clinical trial site readiness.评估临床试验机构准备情况的框架。
J Clin Transl Sci. 2023 May 8;7(1):e151. doi: 10.1017/cts.2023.541. eCollection 2023.
2
Improving the Approach to Defining, Classifying, Reporting and Monitoring Adverse Events in Seriously Ill Older Adults: Recommendations from a Multi-stakeholder Convening.改善对重症老年患者不良事件的定义、分类、报告和监测方法：多利益相关方会议的建议。
J Gen Intern Med. 2023 Feb;38(2):399-405. doi: 10.1007/s11606-022-07646-7. Epub 2022 May 17.
3
Equitable Representation of Latinos in Clinical Research Is Needed to Achieve Health Equity in Cancer Care.
需要在临床研究中公平代表拉丁裔，以实现癌症护理中的健康公平。
JCO Oncol Pract. 2022 May;18(5):e797-e804. doi: 10.1200/OP.22.00127.
4
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe.在德国和欧洲千禧年后法规变更前后，一种用于癌症患者的药物的研究者发起的临床试验的启动情况。
Cancers (Basel). 2022 Mar 3;14(5):1308. doi: 10.3390/cancers14051308.
5
Presence and activities of clinical research coordinators at Italian Health Care Institutions: A national cross-sectional survey.意大利医疗机构临床研究协调员的配备情况与活动：一项全国性横断面调查。
J Clin Transl Sci. 2021 Oct 28;6(1):e1. doi: 10.1017/cts.2021.872. eCollection 2022.
6
Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers.临床试验指标：北美癌症中心进行临床试验的复杂性。
JCO Oncol Pract. 2021 Jan;17(1):e77-e93. doi: 10.1200/OP.20.00501. Epub 2020 Nov 13.
7
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials.3期随机癌症临床试验的试验赞助与报告时间
Cancers (Basel). 2020 Sep 16;12(9):2636. doi: 10.3390/cancers12092636.
8
Clinical Trials in the Age of Pandemics.大流行时代的临床试验
J Natl Compr Canc Netw. 2020 Aug;18(8):1008-1011. doi: 10.6004/jnccn.2020.7588.
9
Making consent for electronic health and social care data research fit for purpose in the 21st century.使21世纪电子健康与社会护理数据研究的同意书符合目的。
BMJ Health Care Inform. 2020 Jul;27(1). doi: 10.1136/bmjhci-2020-100128.
10
Conceptual Model for Accrual to Cancer Clinical Trials.癌症临床试验入组的概念模型
J Clin Oncol. 2019 Aug 10;37(23):1993-1996. doi: 10.1200/JCO.19.00101. Epub 2019 Jun 5.